SinoMab BioScience Ltd

Company Profile

• Business description

  SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) as well as non-Hodgkin’s lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.

• Contact

  No. 15 Science Park West Avenue
  Units 303 and 305 to 307
  Hong Kong Science Park, Pak Shek Kok
  New Territories
  Hong Kong
  HKG

  T: +852 34269833

  https://www.sinomab.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  61